menu
    • menu
    [{"orgOrder":0,"company":"Visirna","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Visirna","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"Visirna \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Visirna \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Visirna

    Menu

    Visirna

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Visirna

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Visirna

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plozasiran

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Sanofi

                            Deal Size : $395.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sanofi Pens $395 M China Pact for Arrowhead Metabolic Med Awaiting Approval Decision

                            Details : Under the licesning agreement, Sanofi will receive an exclusive license to develop and commercialize VSA001 (plozasiran) in China. it is being evaluated for treating familial chylomicronemia syndrome.

                            Product Name : VSA001

                            Product Type : Oligonucleotide

                            Upfront Cash : $130.0 million

                            August 01, 2025

                            Lead Product(s) : Plozasiran

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Sanofi

                            Deal Size : $395.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth